DB:IBPB

Stock Analysis Report

Executive Summary

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Bio-Path Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IBPB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-18.4%

IBPB

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-20.0%

IBPB

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: IBPB exceeded the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: IBPB exceeded the German Market which returned 2.9% over the past year.


Shareholder returns

IBPBIndustryMarket
7 Day-18.4%-11.1%-9.1%
30 Day-32.5%-12.8%-7.2%
90 Day-26.4%-9.6%-6.5%
1 Year-20.0%-20.0%-2.7%-2.9%6.1%2.9%
3 Year-97.3%-97.3%25.8%24.4%3.5%-5.6%
5 Yearn/a1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Bio-Path Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bio-Path Holdings undervalued compared to its fair value and its price relative to the market?

0.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IBPB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IBPB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IBPB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IBPB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IBPB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IBPB is good value based on its PB Ratio (1x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Bio-Path Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-13.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IBPB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IBPB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IBPB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IBPB is forecast to have no revenue next year.

High Growth Revenue: IBPB is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IBPB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bio-Path Holdings performed over the past 5 years?

-13.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBPB is currently unprofitable.

Growing Profit Margin: IBPB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IBPB is unprofitable, and losses have increased over the past 5 years at a rate of -13.8% per year.

Accelerating Growth: Unable to compare IBPB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBPB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: IBPB has a negative Return on Equity (-50.67%), as it is currently unprofitable.


Next Steps

Financial Health

How is Bio-Path Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IBPB's short term assets ($16.9M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: IBPB's short term assets ($16.9M) exceed its long term liabilities ($352.0K).


Debt to Equity History and Analysis

Debt Level: IBPB is debt free.

Reducing Debt: IBPB has not had any debt for past 5 years.


Balance Sheet

Inventory Level: IBPB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IBPB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBPB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IBPB has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -15.7% each year.


Next Steps

Dividend

What is Bio-Path Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IBPB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IBPB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBPB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBPB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBPB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average board tenure


CEO

Peter Nielsen (70yo)

12.1yrs

Tenure

US$671,927

Compensation

Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licen ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD671.93K) is above average for companies of similar size in the German market ($USD419.45K).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Peter Nielsen
Co-Founder12.1yrsUS$671.93k0.70% $129.1k
Douglas Morris
Co-Founder13.1yrsUS$90.76kno data
Jorge Cortes
Chairman of the Scientific Advisory Board4.5yrsno datano data
Martina Molsbergen
Independent Director0.3yrsno datano data
Paul Aubert
Independent Director2yrsUS$48.02kno data
Anas Younes
Member of Scientific Advisory Board1.1yrsno datano data
Jason Fleming
Member of Scientific Advisory Board1.5yrsno datano data
Heath Cleaver
Independent Director6yrsUS$56.79kno data
D. Hooper
Member of Scientific Advisory Board3yrsno datano data

3.0yrs

Average Tenure

54yo

Average Age

Experienced Board: IBPB's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 259.5%.


Top Shareholders

Company Information

Bio-Path Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Path Holdings, Inc.
  • Ticker: IBPB
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.305m
  • Listing Market Cap: US$18.464m
  • Shares outstanding: 3.69m
  • Website: https://www.biopathholdings.com

Number of Employees


Location

  • Bio-Path Holdings, Inc.
  • 4710 Bellaire Boulevard
  • Suite 210
  • Bellaire
  • Texas
  • 77401
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BPTHNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2008
IBPBDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2008

Biography

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 22:50
End of Day Share Price2020/02/28 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.